Any current/future new fundraising through debt or equity?

There is no specific mention of any current or future fundraising through debt or equity in the provided transcript. The company recently completed an IPO during the year, which significantly improved their cash and bank balance (from 35 crores to 208 crores) and liquidity (from 173 crores to 419 crores). They have been cautious in deploying IPO funds, focusing on active due diligence regarding potential acquisitions and internal capability/talent acquisition. Current borrowings have reduced from 54 crores to 42 crores, primarily in PCFC loans aligned with favorable interest rates. No explicit

Any current/future capex/capital investment/strategic investment?

The company is actively deploying IPO funds with a focus on strategic investments, including the ongoing due diligence for a potential acquisition (JBN acquisition in the West). Capital deployment is cautious and targeted, ensuring proper evaluation before committing funds. A significant portion of IPO proceeds is earmarked for talent acquisition to strengthen internal capabilities. There is an emphasis on capability buildup to handle a growing order book pipeline. No specific mention of traditional capex like machinery or plant expansion was noted; the focus appears more on strategic growth a

Current/ Expected Orderbook/ Pending Orders?

Current pipeline/order book is approximately ₹900 crores, expected to be delivered in the next 18 to 24 months. Internal targets for order bookings exceed publicly disclosed numbers but are not fully disclosed. Hot lead pipeline valued around USD 200 million (approx. ₹1,600 crores), growing and being validated. Order conversion timelines depend heavily on client readiness and civil infrastructure; typically, greenfield projects take 24-27 months but recent efforts have reduced this by about 20%. Orders are geographically diversified across UAE, Saudi Arabia, Iraq, Kenya, North Africa (Algeria,

Future growth expectations in sales/revenue/volumes?

The company targets sustained growth of 25-30% in top line/revenue. There's a focus on increasing order pipeline, currently close to USD 200 million in hot leads. Internal targets for order wins surpass publicly announced guidance. Strategic focus on bidding for pre-engineered buildings (PEB) and civil infrastructure to increase ticket sizes and control project timelines. Expansion in cost-effective markets like Africa to penetrate and grow market share. The current order pipeline is expected to deliver over the next 18 to 24 months. FY27 revenue targets were previously guided at INR 530 to 60

Future growth expectations in earnings/operating earnings/profits/EPS?

Fabtech Technologies projects approximately 25% growth in revenue going forward, reflecting sustained robust order pipelines and market expansion. Operational PAT (Profit After Tax) is expected to improve, aiming towards a margin range of 9.9% to 10.5%. The company maintains its FY28 PAT guidance of 12-14%, indicating steady margin expansion. Growth strategy focuses on profitability with sharper capital efficiency and disciplined scaling rather than growth at any cost. Enhanced ticket sizes from bidding on pre-engineered and civil infrastructure products are expected to improve margins. Operat

IN US

Sale is live|00:00:00left today

Fabtech Technologies LtdQ1 FY26Healthcare Services

Fabtech Technologies Ltd Q1 FY26 Earnings Call Analysis

Revenue, margin, capex, fundraise and order book outlook from management commentary.

Price: ₹157P/E: 20.3Market Cap: ₹750 CrSector: Healthcare Services

Management growth scorecard

Revenue

Category 2

Margin

Category 3

Fundraise

Order

Yes

Capex

Yes

2 of 5 growth signals are positive.

Full analysis

Revenue guidance

Category 2

→The company targets sustained growth of 25-30% in top line/revenue.
→There's a focus on increasing order pipeline, currently close to USD 200 million in hot leads.
→Internal targets for order wins surpass publicly announced guidance.
→Strategic focus on bidding for pre-engineered buildings (PEB) and civil infrastructure to increase ticket sizes and control project timelines.
→Expansion in cost-effective markets like Africa to penetrate and grow market share.
→The current order pipeline is expected to deliver over the next 18 to 24 months.
→FY27 revenue targets were previously guided at INR 530 to 600 crores, reflecting consistent growth expectations.
→Margin protection and enhancement strategies are aligned with growth through larger, more integrated projects.
→Internal capabilities and talent acquisition are being strengthened to support growth.
→Guidance includes a PAT margin of 12-14% by FY28, indicating profitable growth expectations.

Margin guidance

Category 3

→Fabtech Technologies projects approximately 25% growth in revenue going forward, reflecting sustained robust order pipelines and market expansion.
→Operational PAT (Profit After Tax) is expected to improve, aiming towards a margin range of 9.9% to 10.5%.
→The company maintains its FY28 PAT guidance of 12-14%, indicating steady margin expansion.
→Growth strategy focuses on profitability with sharper capital efficiency and disciplined scaling rather than growth at any cost.
→Enhanced ticket sizes from bidding on pre-engineered and civil infrastructure products are expected to improve margins.
→Operational excellence and internal margin development are prioritized to support future quarters.
→Cash flow and receivable management remain strategic priorities to support sustainable earnings growth.
→The transition in leadership structure aims to align with long-term strategic growth and stronger profitability objectives.

3 more insights locked — sign up free to unlock

Fundraise plans

→There is no specific mention of any current or future fundraising through debt or equity in the provided transcript.
→The company recently completed an IPO during the year, which significantly improved their cash and bank balance (from 35 crores to 208 crores) and liquidity (from 173 crores to 419 crores).
→They have been cautious in deploying IPO funds, focusing on active due diligence regarding potential acquisitions and internal capability/talent acquisition.
→Current borrowings have reduced from 54 crores to 42 crores, primarily in PCFC loans aligned with favorable interest rates.
→No explicit plans or discussions about additional fundraising through debt or equity were mentioned in the Q&A or management comments.

Order book

Yes

→Current pipeline/order book is approximately ₹900 crores, expected to be delivered in the next 18 to 24 months.
→Internal targets for order bookings exceed publicly disclosed numbers but are not fully disclosed.
→Hot lead pipeline valued around USD 200 million (approx. ₹1,600 crores), growing and being validated.
→Order conversion timelines depend heavily on client readiness and civil infrastructure; typically, greenfield projects take 24-27 months but recent efforts have reduced this by about 20%.
→Orders are geographically diversified across UAE, Saudi Arabia, Iraq, Kenya, North Africa (Algeria, Morocco, Egypt, Ethiopia).
→New orders have been booked in North and West Africa, Middle East, UAE from Q1 onwards.
→No current cancellation risk despite geopolitical challenges; project delays possible but execution ongoing.
→Focus on bidding for pre-engineered buildings (PEB) and civil infra projects to increase ticket sizes and control timelines.

Capex plans

Yes

→The company is actively deploying IPO funds with a focus on strategic investments, including the ongoing due diligence for a potential acquisition (JBN acquisition in the West).
→Capital deployment is cautious and targeted, ensuring proper evaluation before committing funds.
→A significant portion of IPO proceeds is earmarked for talent acquisition to strengthen internal capabilities.
→There is an emphasis on capability buildup to handle a growing order book pipeline.
→No specific mention of traditional capex like machinery or plant expansion was noted; the focus appears more on strategic growth and internal resource enhancement.

How does Fabtech Technologies Ltd rank vs peers in Healthcare Services?

Pro feature

1Fabtech Technologies Ltd

Rev 2Mar 3

See full Healthcare Services sector rankings

Want more stocks like Fabtech Technologies Ltd?

Build an AI portfolio filtered by sector, market cap, and growth rank. Takes 2 minutes.

Build my portfolio